Latest news
Loading news…
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apellis Pharmaceuticals was acquired by Biogen in 2026 for $5.6B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
725
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- Waltham, Massachusetts, United States
Acquisitions by Apellis Pharmaceuticals
Loading columns…
0 of 0Show
Page 1 / 1
Key People at Apellis Pharmaceuticals
Co-founder, President, and Chief Executive Officer
Chief People Officer
Chief Medical Retina Advisor
EU Medical Communications and Information Lead
Senior Director, Discovery Chemistry
CMO
COO
Chief Technical Operations Officer
Chief Research and Development Officer
Chief Innovation Officer
725
professional contacts at Apellis Pharmaceuticals
Contact execs at Apellis Pharmaceuticals →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Apellis Pharmaceuticals
Loading news…
FAQs about Apellis Pharmaceuticals
People who checked this page also checked these
Sectors Apellis Pharmaceuticals invests & acquires in
Browse the full Acquirezy directory.